Related Experiment Video
Updated: Feb 13, 2026

Depletion and Reconstitution of Macrophages in Mice
Published on: August 1, 2012
miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy
Jiajia Xi1, Qian Huang1, Lei Wang2
1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
Abstract:
MicroRNA-21 (miR-21) is one of the most abundant microRNAs in mammalian cells. It has been intensively studied for its role in regulating apoptosis and oncogenic transformation. However, the impact of miR-21 on host anti-tumor immunity remains unknown. Tumor-associated macrophages are a major leukocyte type that infiltrates tumors and predominantly develops into immunosuppressive, tumor-promoting M2-like macrophages. In contrast, the pro-inflammatory M1-like macrophages have tumoricidal activity. In this study, we show that genetic deficiency of miR-21 promotes the polarization of macrophages toward an M1-like phenotype in vivo and in vitro in the presence of tumor cells; thus it confers host mice with enhanced anti-tumor immunity. By downregulating JAK2 and STAT1, miR-21 inhibits the IFN-γ-induced STAT1 signaling pathway, which is required for macrophage M1 polarization. We also show that the expression of miR-21 in macrophages is regulated upon polarization stimuli as well as upon macrophages co-culturing with tumor cells. Thus, tumor cells may stimulate miR-21 expression in tumor-associated macrophages to prevent tumoricidal M1 polarization. However, augmented STAT1 signaling mediated by miR-21 deficiency upregulates PD-L1 expression in macrophages, which is known to inhibit phagocytic anti-tumor activity. This adverse effect can be alleviated by PD-1 blockade; indeed, miR-21 depletion in macrophages and PD-1 antibody treatment offer superior anti-tumor activity than either agent alone. These studies shed lights on potential application of the combination of miR-21 inhibition and immune checkpoint blockade to target the tumor microenvironment.
Insights
MicroRNA-21 deficiency enhances anti-tumor immunity by promoting M1 macrophage polarization. Combining miR-21 inhibition with PD-1 blockade offers superior tumor control.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- MicroRNA-21 (miR-21) is abundant in mammalian cells, regulating apoptosis and oncogenesis.
- Its role in host anti-tumor immunity and macrophage polarization is largely unknown.
- Tumor-associated macrophages often adopt an immunosuppressive M2 phenotype, hindering anti-tumor responses.
Purpose of the Study:
- To investigate the impact of miR-21 on macrophage polarization and anti-tumor immunity.
- To elucidate the molecular mechanisms by which miR-21 influences macrophage phenotype.
- To explore therapeutic strategies combining miR-21 inhibition with immune checkpoint blockade.
Main Methods:
- Genetic deficiency of miR-21 in mice.
- In vitro and in vivo macrophage polarization assays.
- Analysis of JAK2/STAT1 signaling pathway and PD-L1 expression.
- Combination therapy studies with miR-21 depletion and PD-1 blockade.
Main Results:
- miR-21 deficiency promoted M1 macrophage polarization, enhancing anti-tumor immunity.
- miR-21 inhibits the IFN-γ-induced STAT1 pathway by downregulating JAK2 and STAT1.
- Tumor cells can induce miR-21 expression in macrophages to promote M2 polarization.
- miR-21 deficiency increased PD-L1 expression, but this was overcome by PD-1 blockade.
- Combined miR-21 depletion and PD-1 blockade showed superior anti-tumor efficacy.
Conclusions:
- miR-21 plays a critical role in regulating macrophage polarization and tumor immunity.
- Targeting miR-21 can reprogram tumor-associated macrophages towards an anti-tumor phenotype.
- Combination therapy of miR-21 inhibition and PD-1 blockade represents a promising strategy against tumors.
Related Concept Videos
Insensitive Nuclei Enhanced by Polarization Transfer (INEPT)
¹³C NMR: Distortionless Enhancement by Polarization Transfer (DEPT)
Group Polarization
Tumor Immunotherapy
Molecular Shape and Polarity
The Eukaryotic Promoter Region

